2023
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyHormone-sensitive prostate cancerSensitive prostate cancerPositron emission tomographyConventional computerized tomographyDocetaxel chemotherapyClinical trialsProstate cancerCombination of ADTBackbone of treatmentCytoreductive radical prostatectomySequencing of therapyFirst-line treatmentEvaluation of patientsClinical practice guidelinesOngoing clinical trialsAndrogen receptor antagonistPubMed Medline databaseDeprivation therapyInitial managementOverall survivalStaging evaluationBone scanRandomized trials
2022
Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19.
Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.Peer-Reviewed Original ResearchProstate cancerPCa patientsAndrogen receptorCOVID-19Mortality rateYale New Haven Health SystemProtective rolePrevalence of PCaRate of hospitalRetrospective chart reviewExpression of TMPRSS2Rate of hospitalizationProstate cancer patientsAndrogen receptor antagonistProstate cancer casesSARS-CoV-2Institutional review boardDirected therapyChart reviewClinical characteristicsGnRH agonistHormone therapyGnRH antagonistHome medicationsClinical outcomes
2019
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesbeta CateninCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansMaleMiceMice, KnockoutNeuroendocrine CellsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingProtein TransportTranscription Factor 7-Like 2 ProteinXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerEnzalutamide resistanceTranscription factor 4Neuroendocrine differentiationProstate cancerSecond-generation androgen receptor antagonistHuman prostate cancer cell linesLNCaP human prostate cancer cell lineResistant prostate cancerProstate cancer cell linesStandard of careAndrogen receptor antagonistMouse xenograft modelExpression levelsCell linesTCF4 overexpressionCancer cell linesMedian timeClinical benefitReceptor antagonistNeuroendocrine markersMetastatic CaPTreatment resistanceXenograft modelParental cell line
2018
Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
Chong J, Oh W, Liaw B. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets And Therapy 2018, 11: 2141-2147. PMID: 29695920, PMCID: PMC5905496, DOI: 10.2147/ott.s147168.Peer-Reviewed Original ResearchCastration-resistant prostate cancerMetastatic castration-resistant prostate cancerProstate cancerTreatment of metastatic castration-resistant prostate cancerM0 castration-resistant prostate cancerSecond-generation androgen receptor antagonistProstate-specific antigen responseUS Food and Drug Administration approvalFood and Drug Administration approvalMetastasis-free survivalAndrogen receptor antagonistDrug Administration approvalAndrogen-AR complexSPARTAN studyARN-509Survival benefitReceptor antagonistSymptomatic progressionAndrogen receptorRandomized studyAdministration approvalApalutamideAntigen responseTherapeutic agentsNuclear translocation
2014
Enzalutamide: looking back at its preclinical discovery
Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery. Expert Opinion On Drug Discovery 2014, 9: 837-845. PMID: 24820058, DOI: 10.1517/17460441.2014.918947.Peer-Reviewed Original ResearchConceptsCastration-recurrent PCaFirst-line therapyProstate cancerClinical developmentCastration-recurrent prostate cancerStandard first-line therapyAndrogen-AR axisAR agonist activityMetastatic prostate cancerAR nuclear translocationSelective AR modulatorsFurther clinical studiesAndrogen receptor antagonistPre-clinical discoveryDrug clinical developmentSequential therapyOverall survivalTargeted agentsReceptor antagonistClinical studiesPreclinical discoveryNew agentsAR modulatorsAgonist activityFDA approval
1999
Open trial of flutamide for treatment of obsessive-compulsive disorder.
Altemus M, Greenberg B, Keuler D, Jacobson K, Murphy D. Open trial of flutamide for treatment of obsessive-compulsive disorder. The Journal Of Clinical Psychiatry 1999, 60: 442-5. PMID: 10453797, DOI: 10.4088/jcp.v60n0704.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAndrogen receptorEstrogen receptorClassical intracellular androgen receptorsOCD symptomsPrimary outcome measureFuture treatment trialsIntracellular androgen receptorHamilton Rating ScaleGonadal steroid hormonesAndrogen receptor antagonistYale-Brown Obsessive Compulsive ScaleEffect of treatmentBeck Anxiety InventoryLack of responseObsessive Compulsive ScaleOpen trialTreatment trialsReceptor antagonistGonadal steroidsOutcome measuresCompetitive antagonistEstrogen activityFlutamideSteroid hormones
1998
A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome
Peterson B, Zhang H, Anderson G, Leckman J. A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome. Journal Of Clinical Psychopharmacology 1998, 18: 324-331.. PMID: 9690699, DOI: 10.1097/00004714-199808000-00013.Peer-Reviewed Original ResearchConceptsAndrogen receptor blockadeReceptor blockadeCrossover trialHormone levelsSyndrome patientsSelective androgen receptor antagonistAdult TS subjectsTreatment of ticsTourette syndrome patientsTic symptom severitySerious side effectsAndrogen receptor antagonistSymptom severity ratingsTS prevalenceClinic visitsFlutamide administrationEndocrine findingsObsessive-compulsive disorderReceptor antagonistAndrogen receptorPhysiologic compensationTherapeutic effectPhysiologic mechanismsSide effectsTourette syndrome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply